Jennifer Hanlon, MD
Otolaryngology · Miami, FLNPI 1891144911
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,963 of the $5,122 with a category attached, or 77.4%. 19 manufacturers reported payments, led by Sanofi at 40.3% of the total.
Across 103 payments — averaging $49.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$700
- AbbVie$588
- GSK$349
- Aerin Medical Inc.$332
- Medtronic$287
- plus $801 from 13 others
What the payments were for
- Consulting fees$1,06021%
- Food & beverage$3,96377%
- Education$982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 28 | $2,065 |
| Regeneron Healthcare Solutions, Inc. | 22 | $700 |
| AbbVie(2 entities) | 5 | $588 |
| GSK | 14 | $349 |
| Aerin Medical Inc. | 4 | $332 |
| Medtronic | 6 | $287 |
| Optinose US, Inc. | 8 | $153 |
| Johnson & Johnson | 2 | $142 |
| Inspire Medical Systems, Inc. | 1 | $126 |
| Stryker | 1 | $112 |
| Mayne Pharma Commercial LLC | 3 | $71 |
| Sun Pharmaceutical Industries Inc. | 2 | $36 |
| EPI Health, LLC | 1 | $34 |
| Integra Lifesciences Corporation | 1 | $30 |
| Axogen | 1 | $24 |
| LEO Pharma Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Aroa Biosurgery Incorporated | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$494
- BOTOX$422
- VIVAER STYLUS$277
- RHINAER STYLUS$277
- PROPEL$187
- Inspire Upper Airway Stimulation System$126
- MATRIX$120
- UNIVERSAL ORTHOGNATHIC$112
- MINI PLATING SYSTEM (MPS)$112
- UNIVERSAL UPPER-FACE$112
- UNIVERSAL NEURO$112
- CUSTOM IMPLANTS$112
How this compares
$5,122 in reported general payments places this provider in the 80th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $52,997 |
| Fluocinolone Acetonide Oil | 26 | $1,590 |
| Ipratropium Bromide | 38 | $952 |
| Fluticasone Propionate | 35 | $605 |
| Azelastine Hcl | 21 | $558 |
| Famotidine | 33 | $376 |
| Mupirocin | 38 | $330 |
| Omeprazole | 16 | $199 |
| Ondansetron OdtOndansetron | 15 | $87 |
| Clindamycin Hcl | 12 | $79 |
| Cephalexin | 15 | $56 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Miami
- Maria SuurnaMiami$189K
- Agustin ArrietaMiami$95K
- Francisco PernasMiami$70K
- Adrien EshraghiMiami$41K
- Michael HofferMiami$24K
- Corinna LevineMiami$16K
- Jason LeibowitzMiami$13K
- Donald WeedMiami$8K
- Cecelia DamaskOrlando$707K
- Ralph TufanoSarasota$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.